Friday, 16 October 2026European Markets

70% Drop In TERACT BS Stock: Should It Be Time To Sell?

Loading stream...
(vianews) - teract bs (terbs.pa), listed on the cac 40 index, experienced an astonishing 70% fall from eur0.10 to eur0.03 by 16:19 est on monday; this drop occurred despite overall cac 40 index rising 1.32% to eur7,324.80 following an upward trend. teract bs's last closing price was eur0.10, which is below its 52-week high of eur0.10. investors have noted this dip and are closely watching for signs that teract's financial health and business prospects might have worsened.

yearly analysis

based on its current stock price of eur0.03, teract bs has reached its 52-week low point over the last year, meaning that investors should carefully consider all relevant factors before making investment decisions in teract bs. it would also be wise to assess factors such as its financial health, industry trends, and overall market conditions prior to investing.

technical analysis

moving average analysis: teract bsteract bs's current stock price of eur0.06 falls significantly below both its 50-day and 200-day moving averages, both set at eur0.10 respectively, suggesting an imminent downward trend in its share price over short and long terms. investors may be alarmed at this trend as moving averages provide technical indicators of the stock's price trend and widening gaps between its current price and moving averages could suggest further downward movement of its share price. it should be remembered, however, that moving averages are only one indicator used to analyze a stock's performance; other considerations like fundamental analysis as well as market conditions must also be taken into account when analyzing performance of any particular stock. more news about teract bs (terbs.pa).
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com